search

Active clinical trials for "Respiratory Tract (Lung and Bronchial) Diseases"

Results 611-620 of 43232

Efficacy and Safety Evaluation for the Treatment of Asthma and Allergic Rhinitis/Rhinoconjunctivitis...

Allergic RhinoconjunctivitisPerennial Allergic Rhinitis2 more

Prospective, randomized, placebo-controlled, multicenter of 3 active treatment groups, compared to 1 placebo group, for the determination of the efficacy and safety of subcutaneous immunotherapy in patients with mild to moderate asthma and allergic rhinitis/rhinoconjunctivitis (intermittent or persistent) due to hypersensitivity to house dust mites (Dermatophagoides pteronyssinus and / or D. farinae) and grass pollen

Recruiting30 enrollment criteria

Safety and Pharmacokinetics of Ceftolozane/Tazobactam in Pediatric Participants With Nosocomial...

Nosocomial Pneumonia

This is a phase 1, open-label, non-comparative, multicenter clinical study to evaluate the safety, tolerability, and pharmacokinetics of ceftolozane/tazobactam (MK-7625A) in pediatric participants with nosocomial pneumonia (NP).

Recruiting12 enrollment criteria

Effect of CPAP on 6-Minute Walk Test Outcomes in Patients With ECAC

TracheobronchomalaciaExcessive Dynamic Airway Collapse

The purpose of this protocol is to perform a prospective, randomized, double-blinded, pacebo-controlled clinical trial to determine the influence of a non-invasive positive pressure ventilation device on exercise capacity and symptoms in adult patients with ECAC. Primary outcome will include the total distance traversed by the study subject during a standard 6-minute walk test, and secondary outcomes will include peak flow measurement and symptom reporting before and after the exercise testing. The study will focus on the use of continuous positive airway pressure (CPAP) device. CPAP is FDA-approved for the treatment of various medical conditions, including obstructive sleep apnea and heart failure, but is not FDA-approved for the treatment of ECAC. The study will enroll 32 ambulatory study subjects with confirmed ECAC at the BIDMC, and each study subject will be monitored for up to 3 months.

Recruiting14 enrollment criteria

Training Single Arm

Pulmonary Hypertension

The pulmonary hypertension is a disease, which tends to a progredient right heart failure. Although there was a large progress in development of medical therapy, the quality of life, the physical efficiency and the prognosis of the patients are still limited. The aim of the study is to examine the influence of physical training to clinical and molecular parameter.

Recruiting17 enrollment criteria

Technology-Supported Treatment of Sleep Apnea in Prediabetes

Sleep ApneaPreDiabetes1 more

Despite the efficacy of intensive lifestyle interventions in prediabetes, the incidence of diabetes is rising, and thus there is a critical need for additional strategies to prevent diabetes and to reduce its cardiovascular complications in this high-risk population. Sleep apnea is a highly common condition in prediabetes, but it has been mostly ignored and undertreated in current practice. The proposed study will be the first to assess whether adding CPAP (continuous positive air pressure) treatment to a lifestyle intervention improves cardiometabolic outcomes beyond that achieved with lifestyle alone (i.e. current standard of care) in high-risk individuals with prediabetes.

Recruiting6 enrollment criteria

A Study to Assess the Safety, Tolerability, and Pharmacokinetics of Cefiderocol in Hospitalized...

Gram-negative Bacterial InfectionsHospital Acquired Bacterial Pneumonia (HABP)2 more

The primary objectives of this study are to assess the safety, tolerability, and pharmacokinetics (PK) of cefiderocol after single-dose administration in hospitalized pediatric participants 3 months to < 12 years of age with suspected or confirmed aerobic Gram-negative bacterial infections and after multiple-dose administration in hospitalized pediatric participants 3 months to < 18 years of age with suspected or confirmed complicated urinary tract infection (cUTI), hospital-acquired bacterial pneumonia (HABP), or ventilator-associated bacterial pneumonia (VABP).

Recruiting22 enrollment criteria

NK Cells Treatment for COVID-19

Novel Coronavirus Pneumonia

Since december 2019, acute respiratory disease due to 2019 novel coronavirus (2019-nCoV) emerged in Wuhan city and rapidly spread throughout China. There is no confirmed antivirus therapy for 2019-nCoV infection. Natural killer (NK) cells are innate lymphocytes that may serve as useful effectors against danger infection. The purpose of this clinical investigation is to evaluate the safety and efficiency of NK Cells in combination with standard therapy for pneumonia patients infected with 2019-nCoV.

Recruiting8 enrollment criteria

High Intensity Aerobic Exercise Training and Immune Cell Mobilization in Patients With Lung Cancer...

CancerCancer of Lung

The purpose of this study is to investigate if high-intensive training can mobilize and activate the immune system, and thereby enhance the effect of the conventional treatment of lung cancer patients. An important aspect of this study will investigate if the presence of various proteins and cells in blood and tumor biopsies can verify or predict the effect of the high-intensive training. In this clinical trial, patients with lung cancer will combine their conventional therapy with a six-week exercise program.

Recruiting25 enrollment criteria

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With...

Advanced Solid TumorMSI-H/dMMR Tumors10 more

The purpose of this study is to evaluate the safety and tolerability, pharmacokinetics, pharmacodynamics, and early clinical activity of INCB099280 in participants with select solid tumors

Recruiting18 enrollment criteria

Acalabrutinib for the Treatment of Chronic Graft Versus Host Disease

Recurrent Moderate-Severe Chronic Graft Versus Host DiseaseHematopoietic and Lymphoid Cell Neoplasm

This phase II trial studies how well acalabrutinib works in treating patients with chronic graft versus host disease. Acalabrutinib may be an effective treatment for graft-versus-host disease caused by a stem cell transplant.

Recruiting33 enrollment criteria
1...616263...4324

Need Help? Contact our team!


We'll reach out to this number within 24 hrs